Re: Ito et al.: Prognostic Impact of C-reactive Protein for Determining Overall Survival of Patients With Castration-resistant Prostate Cancer Treated With Docetaxel (Urology 2011;78:1131-1135)

摘要

TO THE EDITOR:We read with interest the study by Ito et al, who demonstrated that an elevated C-reactive protein (CRP) concentration is a significant prognostic factor for overall survival in patients with castrate-resistant prostate cancer treated with docetaxel. The risk stratification containing CRP and hemoglobin can be useful for estimating the length of overall survival in these patients. Interleukin-6 (IL-6), produced by prostate cancer cells, is a potent inducer of CRP production and stimulates prostate cancer progression in an autocrine or paracrine manner (from the liver). We congratulate the author for the excellent results.